Trial Profile

A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Milvexian (Primary) ; Aspirin; Clopidogrel
Indications Atherosclerosis; Brain infarction; Ischaemic stroke; Transient ischaemic attacks
Focus Proof of concept; Therapeutic Use
Acronyms AXIOMATIC-SSP
Sponsors Bristol-Myers Squibb

01 Jan 2024 Results reporting efficacy and safety data published in the Lancet Neurology
06 Oct 2022 Status changed from active, no longer recruiting to completed.
28 Aug 2022 According to a Bristol-Myers Squibb media release, results from this trial were presented in a Hot Line session at the European Society of Cardiology (ESC) Congress 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com